SELLAS Life Sciences Q1 net loss widens on higher expenses

Sellas Life Sciences

12/05/2026 21:19

Overview

US biopharmaceutical developer's Q1 net loss widened amid higher operating expenses

Company ended Q1 with $107.1 mln in cash, plus $7.5 mln received in Q2 from warrants

SELLAS nears final analysis for pivotal Phase 3 REGAL trial in AML, with 78 of 80 events reached

Outlook

SELLAS expects topline results from Phase 3 REGAL trial in AML after 80th event is reached

Company expects topline data from Phase 2 SLS009 trial in newly diagnosed AML in Q4 2026

Result Drivers

R&D SPENDING - Co said higher research and development expenses were due to increased manufacturing, clinical, and regulatory consulting costs related to GPS program preparation

ADMINISTRATIVE COSTS - Co said higher general and administrative expenses reflected increased professional fees, consulting, public company costs, and non-cash stock-based compensation

Company press release: ID:nGNX3hNr3z

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$8.41 mln
Q1 Basic EPS
-$0.05
Q1 Operating Expenses
$9.25 mln
Q1 Operating Income
-$9.25 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Sellas Life Sciences Group Inc is $10.00, about 90.5% above its May 11 closing price of $5.25

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)